Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to Crizotinib

ROS1 rearrangements define a distinct molecular subset of non-small-cell lung cancer (NSCLC), which can be treated effectively with crizotinib, a tyrosine kinase inhibitor (TKI) targeting ROS1/MET/ALK rearrangements. Diverse efficacy was observed in ROS1-rearranged NSCLC patients. Because of its rar...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Yueming, Sheng, Wang, Hu, Weiguo, Lin, Jing, Liu, Junjun, Yu, Bing, Mao, Xinru, Zhang, Lu, Huang, Jin, Wang, Guangsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848361/
https://www.ncbi.nlm.nih.gov/pubmed/30940295
http://dx.doi.org/10.3727/096504019X15509372008132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848361/
https://www.ncbi.nlm.nih.gov/pubmed/30940295
http://dx.doi.org/10.3727/096504019X15509372008132

Ejemplares similares